{"analyses":[{"ciLowerLimit":"0.639","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.877","estimateComment":"HR (relative to Lapatinib + Capecitabine) was estimated by Cox regression.","groupDescription":"Analysis stratified by region of enrollment, number of prior chemotherapeutic regimens (0-1 or \\>1), and visceral/ non-visceral disease.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0003","paramType":"Hazard Ratio (HR)","paramValue":"0.749","statisticalMethod":"Log Rank","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"26.32","upperLimit":"34.10","value":"29.9"},{"groupId":"OG001","lowerLimit":"22.74","upperLimit":"28.32","value":"25.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"495"},{"groupId":"OG001","value":"496"}],"units":"Participants"}],"description":"OS was defined as the time from the date of randomization to the date of death from any cause. The median duration of OS was estimated using Kaplan-Meier method. The 95% CI was computed using the method of Brookmeyer and Crowley. The results reported are from the final analysis. The final analysis is descriptive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received trastuzumab emtansine 3.6 mg/kg IV infusion over 30-90 minutes on Day 1 of each 21-day treatment cycle until PD (as assessed by the investigator), unmanageable toxicity, or study termination.","id":"OG000","title":"Trastuzumab Emtansine"},{"description":"Participants received lapatinib 1250 mg (five 250 mg tablets) orally once daily during each 21-day cycle + capecitabine 1000 mg/m\\^2 orally twice daily on Days 1-14 of each 21-day treatment cycle until PD (as assessed by the investigator), unmanageable toxicity, or study termination. Participants of this group were allowed to cross over to receive trastuzumab emtansine based on statistically significant OS benefit in favor of trastuzumab emtansine demonstrated in second interim analysis.","id":"OG001","title":"Lapatinib + Capecitabine"}],"paramType":"MEDIAN","populationDescription":"ITT population included all randomized participants on the basis of the treatment assigned at randomization.","reportingStatus":"POSTED","timeFrame":"From the date of randomization through the data cut-off date of 31 Dec 2014 (up to 5 years, 11 months)","title":"Overall Survival: Final Analysis","type":"PRIMARY","unitOfMeasure":"Months"}